A review on potential of natural products in the management of COVID-19

Rudra Chakravarti,†a Rajveer Singh,†a Arijit Ghosh,†b Dhritiman Dey, a Priyanka Sharma, a Ravichandiran Velayutham, a Syamal Roy*c and Dipanjan Ghosh‡a†

At the end of 2019, a life threatening viral infection (COVID-19) caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was reported. This virus has spread worldwide in a short duration and forced the world to face unprecedented life and economic loss. To date, there are no known specific drugs to combat this virus and the process for new drug development is lengthy. Most promising candidates, which emerged as potential leads, were abandoned in the later phases of clinical trials. Repurposing of already approved drugs for other therapeutic applications can be done only after extensive testing for safety and efficacy. With no definite therapeutics in the horizon, natural products are in extensive use arbitrarily as anti-viral agents and immune boosters. For ages it has been known that most natural products possess potent anti-viral activity and it is no different for SARS-CoV-2. It has been shown that natural products display inhibitory effects on MERS-CoV and SARS-CoV infections. In silico studies have shown that various natural products have strong binding affinity for and inhibitory action on the non-structural proteins of the virus, namely PLpro, Mpro, and RdRp, and structural proteins such as spike (S) protein. Since the virus utilizes the transmembrane ACE2 receptor of the host cell, it also proves to be a valid target for drug development. In this review promising targets for drug development against SARS-CoV-2 and anti-viral activities of some of the known natural products are discussed.

Introduction

Viruses are responsible for the pathogenesis of several human and animal diseases. Modern studies have revealed the link between viruses and diseases like type I diabetes mellitus, hepatitis B virus (HBV) and hepatitis C virus (HCV), hepatocellular carcinoma,2 and Alzheimer’s disease.3 With the increase in urbanization, worldwide travel and immigration, the chances of epidemic outbreaks increase. Recurrences of such viral epidemics can cause a severe threat to public health since there are no proper vaccines and anti-viral therapies for most viral infections.4 In recent years, several viral infection outbreaks have been reported such as the SARS-CoV outbreak in Foshan, China, in 2002,5 avian influenza in humans (2005), H1N1 influenza (2009), MERS-CoV (2012 onwards) and Ebola outbreak in West Africa in 2014,6 to name a few. A more recent explosion of the SARS-CoV-2 has wreaked havoc and has brought humanity to a standstill. According to the data furnished by https://www.worldometers.info/coronavirus/ (retrieved on 26th December, 2020), this virus has infected more than 80 million people worldwide. According to WHO, the most common symptoms of COVID-19 are fever, dry cough and fatigue. Apart from these, some affected people may experience loss of taste and smell, nasal congestion, conjunctivitis, sore throat, muscle and joint pain, diarrhoea, shortness of breath and hyperthermia. WHO also stated that people of all ages are susceptible to this viral infection. People with co-morbidity factors such as high blood pressure, pulmonary problems, obesity, cancer and diabetes are highly vulnerable.7 Although most infected persons experience mild to moderate symptoms, some people may develop Acute Respiratory Distress Syndrome (ARDS). According to a study published in Lancet, the SARS-CoV-2 infection has long-term consequences such as severe fatigue, weight loss and memory loss.8 As of December 2020, there were 60 vaccine candidates in the clinical development phase and 172 vaccine candidates in the pre-clinical development phase.9 Implementing a successful vaccine requires extensive pre-clinical and clinical trials and only after ascertaining the safety and efficacy it can be administered to people. On 28th March, 2020, the US FDA approved hydroxychloroquine sulfate and chloroquine phosphate for use in hospitalized
patients. These two repurposed drugs have been routinely used for decades for the therapy of malaria and autoimmune diseases.\textsuperscript{10} Although these two drugs showed promising results in inhibiting SARS-CoV-2 \textit{in vitro},\textsuperscript{11} there are no convincing shreds of evidence of their effect \textit{in vivo}.\textsuperscript{12} Other FDA approved anti-viral drugs like remdesivir, galidesivir, favipiravir, lopinavir, ribavirin, ritonavir, azithromycin (macrolide antibiotic) and ivermectin (antiparasitic) are being evaluated for the treatment of COVID-19.\textsuperscript{13-15}

SARS-CoV-2, its genome organization, structural proteins and life cycle

SARS-CoV-2 is an enveloped, positive-sense RNA, non-segmented virus of \textit{Sarbecovirus} subgenus and Orthocoronavirinae subfamily, which is broadly distributed in humans and other mammals.\textsuperscript{16,17} The diameter of SARS-CoV-2 is about 65–125 nm and it has crown-like spikes on the outer surface. Like MERS-CoV and SARS-CoV, SARS-CoV-2 is also a \( \beta \)-coronavirus.\textsuperscript{18}

Genome organization

Like other CoVs, SARS-CoV-2 also possesses a large genome of approximately 30 kb containing various genetic characteristics similar to other CoVs.\textsuperscript{18} Its genome starts with a 5’ cap, followed by a leader sequence, 5’ UTR, ORF1ab encoding ORF1ab polyprotein, 3’ end possessing genes encoding structural proteins like spike (S), membrane (M), envelope (E), nucleocapsid (N) and other accessory proteins, 3’ UTR, ending with a poly-A tail\textsuperscript{18} (Fig. 1).

Viral proteins

The SARS-CoV-2 genome encodes proteins possessing different functions, like structural proteins, non-structural proteins and accessory proteins. Out of a total of 29 proteins we will discuss only the critical structural and non-structural proteins.

Polyprotein 1ab synthesized from ORF1ab yields different proteins involved in the transcription, replication and post-translational modification. In SARS-CoV-2 spike protein there are two subunits, S1 and S2. S1 binds to the ACE2 receptor, whereas S2 facilitates the viral entry by viral and host cell membrane fusion.\textsuperscript{19} A unique feature of SARS-CoV-2 spike (S) protein is that it has a functional polybasic cleavage site of 12 nucleotides cleaved by host furin protease.\textsuperscript{20} SARS-CoV-2 S protein has 1273 amino acids and is 180–200 kDa in size.\textsuperscript{21} SARS-CoV-2 envelope (E) protein has 76–109 amino acids, ranging from 8.4 to 12 kDa in size. E protein has a short, only 7–12 amino acids long, hydrophilic amino terminus, but a large hydrophobic transmembrane domain (TMD) consisting of 25 amino acids, and also possesses an extended hydrophilic carboxyl-terminus at the end. The envelope protein of SARS-CoV-2 plays multiple roles in virus pathogenesis,\textsuperscript{22} assembly,\textsuperscript{23} and viral release\textsuperscript{17} and virulence.\textsuperscript{24} The membrane protein (M) of SARS-CoV-2 comprises 222 amino acids and participates in viral assembly.\textsuperscript{25} M protein, along with the nucleocapsid (N) protein, encapsulates the RNA genome.\textsuperscript{26} The predicted molecular weight of SARS-CoV-2 N protein is 46 kDa and it possesses 419 amino acids. N proteins are involved in encasing the viral RNA into ribonucleocapsids (RNP) and enhancing viral genome replication efficiency.

Out of the 16 NSPs of SARS-CoV-2, four primary NSPs are NSP3 or papain like protease 3, NSP5 or 3C like proteinase,
NSP12 or RdRp, and NSP13 or helicase. Papain-like protease or NSP3 is a 200 kDa protein which is responsible for the cleavage at the N-terminus of the replicase polyprotein.27 This largest NSP having 1945 amino acid residues, i.e., NSP3 along with NSP4, plays an essential role in viral replication by assembling the cytoplasmic double-membrane vesicles. It also suppresses the host’s immune response by blocking NF-kappa-β signalling and IRF3. NSP5 or 3CL Pro polypeptide is a 306 amino acids long protein of 33.8 kDa molecular weight.28 The protease activity of 3CL Pro cleaves polyprotein 1ab at 11 different sites to form all the non-structural proteins (NSPs).29 NSP12 or RNA dependent RNA polymerase (RdRp) is the most versatile viral protein responsible for replication and transcription. For its activity, NSP12 needs NSP7 and NSP8, which act as co-factors and also prevent the dissociation of NSP12. NSP12 possesses around 600 base pairs and a molecular weight of probably of 106 kDa.30 SARS-CoV-2 NSP13 or helicase is composed of 601 amino acids and is responsible for the viral RNA remodelling like introducing the 5’-terminal caps, which is essential for recognition sites for translation and splicing of mRNA.31

### Other host proteins

Some host proteins play crucial roles like virus attachment to the host cell membrane and activation of the spike protein for viral entry in the host cell. ACE II comes first on the list as it is responsible for the viral entry.32,33 SARS-CoV-2 spike protein attaches with ACE II to enter into the cell. This attachment of viral and host proteins depends on other host proteases like TMPRSS2 and cathepsin L, responsible for priming of the spike protein that ends up in activating the spike protein of SARS-CoV-2. TMPRSS2 also cleaves the ACE II, which augments the viral entry.44-37 Like TMPRSS2, cathepsin L also cleaves the spike protein but in post-receptor-binding just before viral entry into the cell.38 Finally, another host membrane-bound protease, i.e., furin, cleaves the SARS-CoV-2 spike protein at the furin cleavage site, which is only present in SARS-CoV-2 and in no other coronaviruses.39 The viral proteins as well as the host proteins (Table 1) can be potential targets for drug development against SARS-CoV-2.

### Table 1 List of important viral and host proteins which are targets for drug development

<table>
<thead>
<tr>
<th>S. no.</th>
<th>Target protein</th>
<th>Presence in</th>
<th>Function</th>
<th>Size</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Spike</td>
<td>SARS-CoV-2</td>
<td>Attaches to host cell membrane by interacting with ACE II</td>
<td>180-200 kDa</td>
<td>19-21</td>
</tr>
<tr>
<td>2</td>
<td>Envelope</td>
<td>SARS-CoV-2</td>
<td>Viral assembly, pathogenesis, release</td>
<td>8.4 to 12 kDa</td>
<td>22-24</td>
</tr>
<tr>
<td>3</td>
<td>Membrane</td>
<td>SARS-CoV-2</td>
<td>Encapsulates the RNA genome</td>
<td>Not found</td>
<td>25</td>
</tr>
<tr>
<td>4</td>
<td>Nucleocapsid</td>
<td>SARS-CoV-2</td>
<td>Encodes the viral RNA into ribonucleocapsid (RNP) and enhancing the efficiency of viral genomic replication</td>
<td>46 kDa (predicted)</td>
<td>26</td>
</tr>
<tr>
<td>5</td>
<td>Papain like protease</td>
<td>SARS-CoV-2</td>
<td>Cleaves at the N-terminus of the replicase polyprotein</td>
<td>200 kDa</td>
<td>27</td>
</tr>
<tr>
<td>6</td>
<td>3C like protease</td>
<td>SARS-CoV-2</td>
<td>Cleaves polyprotein 1ab at 11 different sites to produce all the non-structural proteins</td>
<td>33.8 kDa</td>
<td>28 and 29</td>
</tr>
<tr>
<td>7</td>
<td>RNA dependent RNA polymerase</td>
<td>SARS-CoV-2</td>
<td>Viral replication and transcription</td>
<td>106 kDa</td>
<td>30</td>
</tr>
<tr>
<td>8</td>
<td>Helicase</td>
<td>SARS-CoV-2</td>
<td>Formation of 5’-terminal caps for translation and mRNA splicing</td>
<td>66.85 kDa (predicted)</td>
<td>31</td>
</tr>
<tr>
<td>9</td>
<td>Angiotensin converting enzyme II</td>
<td>Vascular endothelia, gastrointestinal system, heart, and kidney</td>
<td>Provides attachment site for SARS-CoV-2 spike protein</td>
<td>92.5 kDa</td>
<td>32 and 33</td>
</tr>
<tr>
<td>10</td>
<td>Trans membrane protease serine 2</td>
<td>Respiratory tracts, gastrointestinal tract, prostate, colon, stomach, salivary gland, urogenital</td>
<td>Cleaves spike and ACE II protein that augment the virus entry</td>
<td>58 kDa</td>
<td>34-37</td>
</tr>
<tr>
<td>11</td>
<td>Cathepsin L</td>
<td>Host cells lysosome</td>
<td>Cleaves the spike protein in post-receptor-binding stage</td>
<td>19 kDa</td>
<td>38</td>
</tr>
<tr>
<td>12</td>
<td>Furin</td>
<td>Lungs, colon, glands, liver, and kidney</td>
<td>Cleaves spike protein at furin cleavage site</td>
<td>86.7 kDa</td>
<td>39</td>
</tr>
</tbody>
</table>
like protease (PRO) and 3C-like protease (3CLPRO) to create functional Non-Structural Proteins (NSPs). The coronavirus genomic RNA encodes two types of proteins, NSPs crucial for viral RNA synthesis and structural proteins necessary for virion assembly.

After translation of structural proteins and NSPs, the Replicase–Transcriptase Complex (RTC) is formed by the assembly of RNA-dependent RNA polymerase (RdRp) (NSP12), helicase (NSP13) and other subunits like NSP7 and NSP8. Further, the complex transcribes a viral genome template of negative-sense genes, including progeny genome and subgenomic RNA as intermediate products, followed by the transcription of positive-sense mRNAs mediated by RdRp.

After transcription, the subgenomic proteins get translated to form structural and accessory proteins such as M, S, and E proteins and encased into the endoplasmic reticulum and then transported to the Endoplasmic Reticulum–Golgi Intermediate Compartment (ERGIC). Next, the previously replicated viral genome can directly join the N protein to form the nucleocapsid that gets insulated into the ERGIC. Finally, nucleocapsids along with several other structural proteins form the virion particles in a vesiculated form, which is exported out of the cell through exocytosis to release virions (Fig. 2).

Potential COVID-19 FDA approved therapeutics in clinical data

COVID-19 is a viral infection that originated from the novel SARS-CoV-2 and led to economic, health, social, and societal ramifications. The lack of an FDA approved line of therapy develops a lot of coercion on scientific and medical teams to generate treatment options. The Food and Drugs Act was established in 1906 to ensure the effectiveness and safety of drug candidates and medical devices. The classical drug development process occurs in different stages: discovery and development, pre-clinical studies, clinical studies, and post-market surveillance (Fig. 3). In the USA, drug development takes approximately 10–12 years, with 9.6 to 13.8% of the total drug candidates passing the FDA policies. The drug discovery step involves selecting and validating thetarget,
lead identification, and then followed by optimization. The pre-clinical phase mainly focuses on manufacturing the active pharmaceutical ingredient, formulation, analytical methods for drug development, ADMET parameters, and Good Manufacturing Practices (GMP). When API passes the above studies, phase I of the clinical trial stage can be initiated. This phase contains 20 to 100 human candidates with the primary goal of the measurement of the dose and safety profile. In phase II clinical trials, the number of human candidates increase to analyse the drug’s effectiveness and its adverse effects. Phase III, with human candidates being more than 3000, intends to compare the participant drug’s efficacy with existing treatments. When the drug candidates pass the above phases, the scrutinizer files the New Drug Application via the FDA, which takes approximately ten months for approval for further studies. Phase IV is considered the post-market surveillance to monitor the drug safety further.

Researchers have analysed the existing information related to the replication and life cycle of SARS-CoV-2 to design the therapeutics of COVID-19. Repurposing of FDA approved drugs for the therapeutics of COVID-19 is the fastest path to create a safe and potential treatment. Hydroxychloroquine, a medicine for the cure and treatment of autoimmune disorders and malaria, was first investigated to treat SARS-CoV-2. Another traditional anti-viral drug remdesivir has shown effectiveness in earlier human CoV outbreaks. Remdesivir is an analogue of adenosine GS-441524, which acts via RNA-dependent RNA polymerase inhibition and active against most RNA-dependent viruses. Remdesivir has primarily been investigated as a SARS-CoV and MERS-CoV regimen in pre-clinical and clinical trials. In 2017, a study on remdesivir proved its efficacy against MERS-CoV, SARS-CoV, and bat CoV, which indicates its broad-spectrum anti-human CoV activity. In cell culture studies, remdesivir showed an effective concentration, i.e., EC$_{50}$ of 0.069 μM against SARS-CoV and 0.074 μM for MERS-CoV. In an animal model, remdesivir significantly reduced the viral load of the lung up to >2 order of magnitude in 4 days of post-infection. Furthermore, remdesivir is used as a prophylactic in SARS-CoV to improve the respiratory function and clinical symptoms. Remdesivir proved its potential against the SARS-CoV in *in vitro* and *in vivo* studies. Still, it was unclear whether the potential shown in SARS-CoV is generalizable to SARS-CoV-2 without further research. Before COVID-19, remdesivir was a potential drug with a fully documented safety and efficacy profile in human trials and pre-clinical trials in various RNA viruses. The first study of remdesivir was conducted by Grein et al., published in NEJM for the treatment of COVID-19. The primary goal of the study was to analyze the safety and efficacy of remdesivir in humans. They selected 53 patients, and remdesivir was injected intravenously for ten days. The authors concluded that after 18 days, 25 patients successfully recovered, 17 patients were extubated from mechanical ventilation, and seven patients died. The FDA has approved chloroquine for the treatment of systemic lupus erythematosus and rheumatoid arthritis. In early studies, chloroquine inhibited antigen processing via endosomal/lysosomal and viral replication. In animal models, chloroquine enhanced the survival rates in new born human coronavirus infected mice. Chloroquine and hydroxychloroquine were the only credible options in China during December 2019 to manage SARS-CoV-2 due to existing *in vitro* studies. A study conducted by Yao et al. showed that hydroxychloroquine is a better option in the safety profile for the treatment of COVID-19 than chloroquine. Hence this drug was an attractive candidate for the management of COVID-19 specifically, having FDA approval for the different indications with well-maintained documents. An alternative regimen, a combination of azithromycin with antimalarial drugs, was thought to be efficacious for the treatment of SARS-CoV-2. The combination of azithromycin with chloroquine and hydroxychloroquine was found to be beneficial for SARS-CoV-2 patients clinically, with no fatalities. The cardiotoxicity caused by the antimalarial drugs alone or combined with azithromycin increases the adverse reactions, which raised the question whether the drugs can be used separately or in combination. In the reported cohort study, azithromycin with chloroquine/hydroxychloroquine prolonged the QT intervals. Azithromycin did not prolong the QT intervals clinically, but the combination regimen significantly prolonged the QT interval.
study was conducted to measure the risk of hydroxychloroquine alone and its combination with azithromycin in rheumatoid arthritis patients. The study concluded that combination therapy of hydroxychloroquine with azithromycin increases the danger of 30 day cardiovascular mortality, chest pain, angina, and cardiac failure.69 These studies suggested that the combination of chloroquine/hydroxychloroquine with azithromycin may be avoidable for the management of SARS-CoV-2.

Current approaches for the management of COVID-19

Apart from the anti-viral drug therapy, clinicians are looking towards an immunotherapeutic approach through Convalescent Plasma Therapy (CPT).70 While the anti-viral drugs are under clinical trials CPT emerges out as a possible line of treatment for COVID-19. This adaptive immunotherapy involves the administration of plasma collected from recovered subjects to the infected ones. The plasma contains a high titer of neutralizing antibody, which can provide an anti-viral effect.71 Studies have shown that CPT is efficacious against COVID-19, and no severe adverse reactions were associated with this therapy.72 Other studies also indicated the same aspect of this therapy. For example, in a Chinese pilot study (ChiCTR2000030046), 10 critically ill patients were all given a 200 ml CP dose with a neutralizing antibody titre >1 : 640. Out of ten, seven patients showed a remarkable improvement clinically and radiologically and reduced viral load.73 Another study showed an improvement of the Sequential Organ Failure Assessment (SOFA) score from 2–10 before CPT to 1–4 after 12 days of therapy.74 This study also revealed that in 5 critically ill patients, the titre value of the virus specific IgG and IgM was significantly higher and the viral infection’s progression was lowered in all the patients. The potential drawback of this line of therapy was that upon implementation of CPT in MERS-CoV infected patients, a study showed a rapid decrease in the antibody titer within three months of the treatment. Another drawback of CPT is the anticipation of transfusion-transmitted infection since transfusion is involved in the therapy. Critically ill patients with impaired lung functions are particularly susceptible to Transfusion Related Acute Lung Injury (TRALI).75 TRALI is caused by anti-human leukocyte antigen (HLA) antibody,76 and such cases have been reported for CPT in Ebola virus outbreak.77 It is recommended to carry out anti HLA antibody screening before implementing CPT for COVID-19.78 Lastly, to render CPT effective, the procurement and utilization of the plasma must be in accordance with the scrupulous ethical guidelines since this is of human origin.79

The rationale for considering natural products as a potential line of treatment for COVID-19

The drugs mentioned above and the CPT confer some relief to the pandemic situation. Still, the exorbitant therapy, limited availability, unprecedented adverse effects of the drugs and ethical concerns regarding CPT make them difficult to implement worldwide. Moreover, the situation can be exacerbated by the mutation of the virus leading to drug-resistant mutants, which would render the anti-viral drugs useless since most of them target specific viral proteins.79–81 Thus we can look for potential therapeutics from the point of view of natural products. A large number of studies have been conducted on anti-viral effects of natural products and herbal medicines. Extensive studies have shed some light on these natural products’ mechanism of action and the possible targets like viral entry, replication, assembly, release, and virus–host specific interactions.82 In the following sections of this review, we have discussed some of the potential anti-viral compounds used for the management and prophylaxis of COVID-19.

Role of polyphenols in combating the SARS COVID-19 pandemic

Potential therapies for SARS-CoV-2 can be categorized into two groups based on targets; drugs that target the virus and drugs that target the host and its immune system.83 The target proteins in SARS-CoV-2 are categorized as non-structural proteins (M^{NSP}, E^{NSP} and RdRp) and spike protein (S protein) (Table 1). Resveratrol, a well-known phytoalexin, showed potent inhibitory action against MERS-CoV in an in vitro study. The same study also indicated that resveratrol could prolong the cellular survival after viral infection.84 Emodin, an anthraquinone polyphenol found in the roots of rhubarb, was found to inhibit the interaction of ACE2 and S protein (Table 1).85 Molecular docking studies have shown that polyphenols from Curcuma sp. (curcumin and its derivatives) and Citrus sp. (hesperetin, hesperidin, and tangeretin) have a stronger binding affinity for the S protein than the reference compound nafamostat.86 Naringenin was found to have more substantial binding energy to viral spike glycoprotein (PDB: 6VSB) than remdesivir,87 an anti-viral which was approved by the FDA for the therapy of COVID-19.88 Tetra-O-galloyl-β-D-glucose (TGG) and luteolin were found to bind with SARS-CoV surface protein and thus hinder the virus’s entry into the host cell.89

The target for the binding of the SARS-CoV-2 is the ACE2, which is a transmembrane metallocarboxypeptidase.90 This receptor thus serves as a potential target for anti-viral drug discovery. Eriodictyol, a flavonone found in Eriodictyon californicum, showed the highest affinity for ACE2 among 77 candidates.91 Although in silico studies can identify promising candidates, more in vitro and in vivo studies are required to assess their actual impact on the pandemic. A study found that mice having inactivated or knocked-out ACE2 developed severe SARS-CoV infection, and they sustained lung injury worse than the wild type control group. The symptoms were alleviated upon administration of recombinant ACE2.92 A cell-based assay revealed that the entry of both SARS-CoV and SARS-CoV-2 was blocked when soluble ACE2 was introduced, thus confirming that recombinant ACE2 can be used as a decoy target against
viral S protein. Since ACE2 plays a vital role in human physiology, targeting it for anti-viral drug discovery should be done after careful assessment of its risks. Protease inhibitors are a class of compounds that have been extensively used in the management of viruses like HIV, MERS-CoV and SARS-CoV. The structural and non-structural proteins essential for the life cycle of the coronavirus are proteolytically processed from the polyprotein by 3CLpro (Mpro) and the PLpro. Natural products like diarylheptanoids, terpenoids, flavonoids and coumarins are potent inhibitors of the SARS-CoV proteases. In silico and in vitro analyses have found that epigallocatechin gallate (EC50 = 73 µM), gallocatechin gallate (EC50 = 47 µM) and quercetin (IC50 = 73 µM) are potent inhibitors of the SARS-CoV-2 Mpro. Flavonoids such as kaempferol and iso-liquiritigenin synergistically inhibited the SARS-CoV-2 Mpro and PLpro in vitro. Gentile et al. screened a library of Marine Natural Products (MNP Library) and identified potent inhibitors of the SARS-CoV-2 Mpro via molecular docking analysis. The potent inhibitors of the viral Mpro were heptaprenahulol A, phlor-ethopentahulol B, pseudopentahulol C, phlor-ethopentahulol A, hydroxypentahulol A and pentaphoroethol B, 1,3,5-trihyroxybenzene from Sargassum spinuligerum and 8,8'-biekol, 6,6'-biekol and diekcol from Ecklonia cava. Flavonoids from traditional Chinese medicines, like herbacetin, rhoifolin, and pectolinarin, were found to inhibit the Mpro of SARS-CoV. Jo et al. found that flavonoids like herbacetin, isobavachalcone and helichrysetin have potent inhibitory properties.

The role of terpenoids and glycosides in combating the COVID-19 pandemic

Terpenoids or isoprenoids are a diverse class of natural compounds derived from isoprene (5 carbon compound) units. The isoprene monomers polymerize to form terpenes. Terpenoids have numerous medicinal properties like anti-viral activity, antibacterial activity, anti-oxidant activity, etc. Wen et al. studied the effect of more than 200 naturally occurring terpenoids and lignoids against SARS-CoV. The virus induced cytopathogenic activity of the compounds was studied on VERO E6 cell lines and they found that the most potent inhibitory compounds were ferrarugoin, [8-β-hydroxyabietate-9(11),13-dien-12-one], 7-β-hydroxydeoxycryptojaponol, 3-β,12-diaacetoxylabieta-6,8,11,13-tetraene and betulonic acid. The same study showed that betulinic acid and savinin were competitive inhibitors of the SARS-CoV Mpro. A recent in silico study
<table>
<thead>
<tr>
<th>S. no.</th>
<th>Name of natural product</th>
<th>Structure</th>
<th>Class of the compound</th>
<th>Potential target(s) (Table 1)</th>
<th>Possible mechanism of action of the compounds</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Emodin</td>
<td><img src="image1" alt="Emodin structure" /></td>
<td>Anthraquinone polyphenol</td>
<td>Host ACE2 receptor and viral S protein</td>
<td>Inhibition of viral entry in host cell</td>
<td>85</td>
</tr>
<tr>
<td>2</td>
<td>Curcumin and its derivatives</td>
<td><img src="image2" alt="Curcumin structure" /></td>
<td>Flavonoid polyphenol</td>
<td>MERS-CoV S protein</td>
<td>Inhibition of viral entry in host cell</td>
<td>86</td>
</tr>
<tr>
<td>3</td>
<td>Hesperetin</td>
<td><img src="image3" alt="Hesperetin structure" /></td>
<td>Flavonoid polyphenol</td>
<td>MERS-CoV S protein</td>
<td>Inhibition of viral entry in host cell</td>
<td>86</td>
</tr>
<tr>
<td>4</td>
<td>Hesperidin</td>
<td><img src="image4" alt="Hesperidin structure" /></td>
<td>Flavonoid polyphenol</td>
<td>MERS-CoV S protein</td>
<td>Inhibition of viral entry in host cell</td>
<td>86</td>
</tr>
<tr>
<td>5</td>
<td>Tangeretin</td>
<td><img src="image5" alt="Tangeretin structure" /></td>
<td>Flavonoid polyphenol</td>
<td>MERS-CoV S protein</td>
<td>Inhibition of viral entry in host cell</td>
<td>86</td>
</tr>
<tr>
<td>6</td>
<td>Naringenin</td>
<td><img src="image6" alt="Naringenin structure" /></td>
<td>Flavanone</td>
<td>SARS-CoV-2 S protein</td>
<td>Inhibition of viral entry in host cell</td>
<td>87</td>
</tr>
<tr>
<td>7</td>
<td>TGG</td>
<td><img src="image7" alt="TGG structure" /></td>
<td>Polyphenol</td>
<td>SARS-CoV S protein</td>
<td>Inhibition of viral entry in host cell</td>
<td>89</td>
</tr>
<tr>
<td>8</td>
<td>Luteolin</td>
<td><img src="image8" alt="Luteolin structure" /></td>
<td>Tetrahydroxy flavone</td>
<td>SARS-CoV S protein</td>
<td>Inhibition of viral entry in host cell</td>
<td>89</td>
</tr>
<tr>
<td>9</td>
<td>Eriodictyol</td>
<td><img src="image9" alt="Eriodictyol structure" /></td>
<td>Flavanone</td>
<td>Host ACE2 transmembrane receptor</td>
<td>Inhibition of viral entry in host cell</td>
<td>91</td>
</tr>
<tr>
<td>S. no.</td>
<td>Name of natural product</td>
<td>Structure</td>
<td>Class of the compound</td>
<td>Potential target(s) (Table 1)</td>
<td>Possible mechanism of action of the compounds</td>
<td>Ref.</td>
</tr>
<tr>
<td>--------</td>
<td>------------------------</td>
<td>-----------</td>
<td>-----------------------</td>
<td>------------------------------</td>
<td>-----------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>10</td>
<td>Epigallocatechin gallate</td>
<td><img src="image1.png" alt="Structure" /></td>
<td>Catechin polyphenol</td>
<td>SARS-CoV M&lt;sup&gt;PRo&lt;/sup&gt;, SARS-CoV-2 M&lt;sup&gt;PRo&lt;/sup&gt;</td>
<td>Inhibition of viral life cycle inside host</td>
<td>101 and 102</td>
</tr>
<tr>
<td>11</td>
<td>Gallocatechin gallate</td>
<td><img src="image2.png" alt="Structure" /></td>
<td>Catechin polyphenol</td>
<td>SARS-CoV M&lt;sup&gt;PRo&lt;/sup&gt;, SARS-CoV-2 M&lt;sup&gt;PRo&lt;/sup&gt;</td>
<td>Inhibition of viral life cycle inside host</td>
<td>101 and 102</td>
</tr>
<tr>
<td>12</td>
<td>Quercetin</td>
<td><img src="image3.png" alt="Structure" /></td>
<td>Flavonoid</td>
<td>SARS-CoV S protein, SARS-CoV M&lt;sup&gt;PRo&lt;/sup&gt;</td>
<td>Inhibition of viral entry in host cell, inhibits viral life cycle in the host</td>
<td>101 and 102</td>
</tr>
<tr>
<td>13</td>
<td>Heptafuhalol A</td>
<td><img src="image4.png" alt="Structure" /></td>
<td>Marine phorethol</td>
<td>SARS-CoV-2 M&lt;sup&gt;PRo&lt;/sup&gt;</td>
<td>Inhibition of viral life cycle inside host</td>
<td>104</td>
</tr>
<tr>
<td>14</td>
<td>Phlorethopenta fuhalol B</td>
<td><img src="image5.png" alt="Structure" /></td>
<td>Marine phorethol</td>
<td>SARS-CoV-2 M&lt;sup&gt;PRo&lt;/sup&gt;</td>
<td>Inhibition of viral life cycle inside host</td>
<td>104</td>
</tr>
<tr>
<td>15</td>
<td>Pseudopenta fuhalol C</td>
<td><img src="image6.png" alt="Structure" /></td>
<td>Marine phorethol</td>
<td>SARS-CoV-2 M&lt;sup&gt;PRo&lt;/sup&gt;</td>
<td>Inhibition of viral life cycle inside host</td>
<td>104</td>
</tr>
</tbody>
</table>
Table 2 (Contd.)

<table>
<thead>
<tr>
<th>S. no.</th>
<th>Name of natural product</th>
<th>Structure</th>
<th>Class of the compound</th>
<th>Potential target(s) (Table 1)</th>
<th>Possible mechanism of action of the compounds</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>Phlorethopenta fuhalol A</td>
<td><img src="image1" alt="Structure" /></td>
<td>Marine phorethol</td>
<td>SARS-CoV-2 M^PRO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>104</td>
</tr>
<tr>
<td>17</td>
<td>Hydroxypenta fuhalol A</td>
<td><img src="image2" alt="Structure" /></td>
<td>Marine phorethol</td>
<td>SARS-CoV-2 M^PRO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>104</td>
</tr>
<tr>
<td>18</td>
<td>Pentaphlorethol B</td>
<td><img src="image3" alt="Structure" /></td>
<td>Marine phorethol</td>
<td>SARS-CoV-2 M^PRO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>104</td>
</tr>
<tr>
<td>19</td>
<td>6,6'-Bieckol</td>
<td><img src="image4" alt="Structure" /></td>
<td>Polyphenol</td>
<td>SARS-CoV-2 M^PRO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>83</td>
</tr>
<tr>
<td>20</td>
<td>Dieckol</td>
<td><img src="image5" alt="Structure" /></td>
<td>Polyphenol</td>
<td>SARS-CoV-2 M^PRO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>83</td>
</tr>
<tr>
<td>21</td>
<td>Herbacetin</td>
<td><img src="image6" alt="Structure" /></td>
<td>Flavonol</td>
<td>SARS-CoV-2 M^PRO MERS CoV M^PRO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>105 and 106</td>
</tr>
<tr>
<td>S. no.</td>
<td>Name of natural product</td>
<td>Structure</td>
<td>Class of the compound</td>
<td>Potential target(s) (Table 1)</td>
<td>Possible mechanism of action of the compounds</td>
<td>Ref.</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------</td>
<td>-----------</td>
<td>-----------------------</td>
<td>-------------------------------</td>
<td>-----------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>22</td>
<td>Rhoifolin</td>
<td><img src="image1" alt="Rhoifolin structure" /></td>
<td>Flavonoid glycoside</td>
<td>SARS-CoV-2 M^P_{RO}</td>
<td>Inhibition of viral life cycle inside host</td>
<td>105</td>
</tr>
<tr>
<td>23</td>
<td>Pectolinarin</td>
<td><img src="image2" alt="Pectolinarin structure" /></td>
<td>Flavonoid glycoside</td>
<td>SARS-CoV-2 M^P_{RO}</td>
<td>Inhibition of viral life cycle inside host</td>
<td>105</td>
</tr>
<tr>
<td>24</td>
<td>Isobavachalcone</td>
<td><img src="image3" alt="Isobavachalcone structure" /></td>
<td>Chalcone polyphenol</td>
<td>MERS-CoV M^P_{RO}</td>
<td>Inhibition of viral life cycle inside host</td>
<td>106</td>
</tr>
<tr>
<td>25</td>
<td>Helichrysetin</td>
<td><img src="image4" alt="Helichrysetin structure" /></td>
<td>Polyphenol</td>
<td>MERS-CoV M^P_{RO}</td>
<td>Inhibition of viral life cycle inside host</td>
<td>106</td>
</tr>
<tr>
<td>26</td>
<td>Glucogallin</td>
<td><img src="image5" alt="Glucogallin structure" /></td>
<td>Tannin</td>
<td>SARS-CoV-2 M^P_{RO}, host TMPRSS2</td>
<td>Inhibition of viral entry into host, inhibition of viral life cycle inside host</td>
<td>108</td>
</tr>
<tr>
<td>27</td>
<td>Mangiferin</td>
<td><img src="image6" alt="Mangiferin structure" /></td>
<td>Xanthone</td>
<td>SARS-CoV-2 M^P_{RO}, host TMPRSS2</td>
<td>Inhibition of viral entry into host, inhibition of viral life cycle inside host</td>
<td>108</td>
</tr>
<tr>
<td>28</td>
<td>Phlorizin</td>
<td><img src="image7" alt="Phlorizin structure" /></td>
<td>Flavonoid glycoside</td>
<td>SARS-CoV-2 M^P_{RO}, host TMPRSS2</td>
<td>Inhibition of viral entry into host, inhibition of viral life cycle inside host</td>
<td>108</td>
</tr>
<tr>
<td>29</td>
<td>Berberine</td>
<td><img src="image8" alt="Berberine structure" /></td>
<td>Isoquinoline alkaloid</td>
<td>SARS-CoV nucleic acid intercalation</td>
<td>Inhibition of viral replication</td>
<td>115–118</td>
</tr>
<tr>
<td>30</td>
<td>Berbamine</td>
<td><img src="image9" alt="Berbamine structure" /></td>
<td>Isoquinoline alkaloid</td>
<td>SARS-CoV nucleic acid intercalation</td>
<td>Inhibition of viral replication</td>
<td>115–118</td>
</tr>
<tr>
<td>S. no.</td>
<td>Name of natural product</td>
<td>Structure</td>
<td>Class of the compound</td>
<td>Potential target(s) (Table 1)</td>
<td>Possible mechanism of action of the compounds</td>
<td>Ref.</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------</td>
<td>-----------</td>
<td>-----------------------</td>
<td>-------------------------------</td>
<td>-----------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>31</td>
<td>Berberrubine</td>
<td></td>
<td>Isoquinoline alkaloid</td>
<td>SARS-CoV nucleic acid intercalation</td>
<td>Inhibition of viral replication</td>
<td>115–118</td>
</tr>
<tr>
<td>32</td>
<td>Coptisine</td>
<td></td>
<td>Isoquinoline alkaloid</td>
<td>SARS-CoV nucleic acid intercalation</td>
<td>Inhibition of viral replication</td>
<td>115–118</td>
</tr>
<tr>
<td>33</td>
<td>Dicentrine</td>
<td></td>
<td>Isoquinoline alkaloid</td>
<td>SARS-CoV nucleic acid intercalation</td>
<td>Inhibition of viral replication</td>
<td>115–118</td>
</tr>
<tr>
<td>34</td>
<td>Jatrorrhizine</td>
<td></td>
<td>Isoquinoline alkaloid</td>
<td>SARS-CoV nucleic acid intercalation</td>
<td>Inhibition of viral replication</td>
<td>115–118</td>
</tr>
<tr>
<td>35</td>
<td>Palmatine</td>
<td></td>
<td>Isoquinoline alkaloid</td>
<td>SARS-CoV nucleic acid intercalation</td>
<td>Inhibition of viral replication</td>
<td>115–118</td>
</tr>
<tr>
<td>36</td>
<td>Tetrandrine</td>
<td></td>
<td>Isoquinoline alkaloid</td>
<td>SARS-CoV nucleic acid intercalation</td>
<td>Inhibition of viral replication</td>
<td>115–118</td>
</tr>
<tr>
<td>37</td>
<td>Fangchinoline</td>
<td></td>
<td>Isoquinoline alkaloid</td>
<td>SARS-CoV nucleic acid intercalation</td>
<td>Inhibition of viral replication</td>
<td>115–118</td>
</tr>
<tr>
<td>S. no.</td>
<td>Name of natural product</td>
<td>Structure</td>
<td>Class of the compound</td>
<td>Potential target(s) (Table 1)</td>
<td>Possible mechanism of action of the compounds</td>
<td>Ref.</td>
</tr>
<tr>
<td>-------</td>
<td>------------------------</td>
<td>-----------</td>
<td>----------------------</td>
<td>-----------------------------</td>
<td>-----------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>38</td>
<td>Cepharanthine</td>
<td><img src="image1" alt="Structure" /></td>
<td>Isoquinoline alkaloid</td>
<td>SARS-CoV nucleic acid intercalation</td>
<td>Inhibition of viral replication</td>
<td>115–118</td>
</tr>
<tr>
<td>39</td>
<td>Schizanthine Z</td>
<td><img src="image2" alt="Structure" /></td>
<td>Tropane alkaloid</td>
<td>SARS-CoV-2 PL&lt;sup&gt;PrO&lt;/sup&gt;</td>
<td>Inhibition of viral life cycle inside host</td>
<td>119</td>
</tr>
<tr>
<td>40</td>
<td>10-Hydroxyusambarensine</td>
<td><img src="image3" alt="Structure" /></td>
<td>Indole alkaloid</td>
<td>SARS-CoV-2 M&lt;sup&gt;PrO&lt;/sup&gt;, SARS-CoV M&lt;sup&gt;PrO&lt;/sup&gt;, MERS CoV M&lt;sup&gt;PrO&lt;/sup&gt;</td>
<td>Inhibition of viral life cycle inside host</td>
<td>122</td>
</tr>
<tr>
<td>41</td>
<td>Cryptoquindoline</td>
<td><img src="image4" alt="Structure" /></td>
<td>Indole alkaloid</td>
<td>SARS-CoV-2 M&lt;sup&gt;PrO&lt;/sup&gt;, SARS-CoV-2 RdRp</td>
<td>Inhibition of viral life cycle inside host</td>
<td>122</td>
</tr>
<tr>
<td>42</td>
<td>Cryptospiridoline</td>
<td><img src="image5" alt="Structure" /></td>
<td>Indole alkaloid</td>
<td>SARS-CoV-2 M&lt;sup&gt;PrO&lt;/sup&gt;, SARS-CoV-2 RdRp</td>
<td>Inhibition of viral life cycle inside host</td>
<td>122 and 123</td>
</tr>
<tr>
<td>43</td>
<td>Cryptomisrine</td>
<td><img src="image6" alt="Structure" /></td>
<td>Indole alkaloid</td>
<td>SARS-CoV-2 RdRp</td>
<td>Inhibition of viral life cycle inside host</td>
<td>123</td>
</tr>
<tr>
<td>S. no.</td>
<td>Name of natural product</td>
<td>Structure</td>
<td>Class of the compound</td>
<td>Potential target(s) (Table 1)</td>
<td>Possible mechanism of action of the compounds</td>
<td>Ref.</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------</td>
<td>-----------</td>
<td>-----------------------</td>
<td>-----------------------------</td>
<td>---------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>44</td>
<td>Biscryptolepine</td>
<td><img src="image1" alt="Structure" /></td>
<td>Indole alkaloid</td>
<td>SARS-CoV-2 RdRp</td>
<td>Inhibition of viral life cycle inside host</td>
<td>123</td>
</tr>
<tr>
<td>45</td>
<td>Anisotine</td>
<td><img src="image2" alt="Structure" /></td>
<td>Quinolone alkaloid</td>
<td>SARS-CoV-2 MPRO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>124</td>
</tr>
<tr>
<td>46</td>
<td>Adhatodine</td>
<td><img src="image3" alt="Structure" /></td>
<td>Quinoline alkaloid</td>
<td>SARS-CoV-2 MPRO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>124</td>
</tr>
<tr>
<td>47</td>
<td>Vasicoline</td>
<td><img src="image4" alt="Structure" /></td>
<td>Quinoline alkaloid</td>
<td>SARS-CoV-2 MPRO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>124</td>
</tr>
<tr>
<td>48</td>
<td>Vasicine</td>
<td><img src="image5" alt="Structure" /></td>
<td>Quinoline alkaloid</td>
<td>SARS-CoV-2 MPRO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>124</td>
</tr>
<tr>
<td>49</td>
<td>Betulinic acid</td>
<td><img src="image6" alt="Structure" /></td>
<td>Pentacyclic triterpenoid</td>
<td>SARS-CoV-2 MPRO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>128</td>
</tr>
<tr>
<td>50</td>
<td>Savinin</td>
<td><img src="image7" alt="Structure" /></td>
<td>Benzodioxole lignan</td>
<td>SARS-CoV-2 MPRO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>128</td>
</tr>
<tr>
<td>51</td>
<td>Thymoquinone</td>
<td><img src="image8" alt="Structure" /></td>
<td>Monoterpene</td>
<td>SARS-CoV MPRO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>129</td>
</tr>
<tr>
<td>52</td>
<td>Salvinorin A</td>
<td><img src="image9" alt="Structure" /></td>
<td>Terpenoid</td>
<td>SARS-CoV MPRO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>129</td>
</tr>
<tr>
<td>S. no.</td>
<td>Name of natural product</td>
<td>Class of the compound</td>
<td>Potential target(s) (Table 1)</td>
<td>Possible mechanism of action of the compounds</td>
<td>Ref.</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>------------------------</td>
<td>-----------------------</td>
<td>-------------------------------</td>
<td>---------------------------------------------</td>
<td>-----</td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>Bilobalide</td>
<td>Terpenic tri lactone</td>
<td>SARS-CoV M₃RO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>129</td>
<td></td>
</tr>
<tr>
<td>54</td>
<td>Citral</td>
<td>Monoterpenes</td>
<td>SARS-CoV M₃RO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>129</td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>Menthol</td>
<td>Monoterpenes</td>
<td>SARS-CoV M₃RO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>129</td>
<td></td>
</tr>
<tr>
<td>56</td>
<td>Ginkgolide A</td>
<td>Diterpene</td>
<td>SARS-CoV M₃RO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>129</td>
<td></td>
</tr>
<tr>
<td>57</td>
<td>Noscapine</td>
<td>Isoquinoline alkaloid</td>
<td>SARS-CoV M₃RO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>129</td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>Forskolin</td>
<td>Labdane terpenoid</td>
<td>SARS-CoV M₃RO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>129</td>
<td></td>
</tr>
<tr>
<td>59</td>
<td>β-Selinene</td>
<td>Sesquiterpenes</td>
<td>SARS-CoV M₃RO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>129</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td>Celastrol</td>
<td>Quinone methide triterpene</td>
<td>SARS-CoV M₃RO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>130</td>
<td></td>
</tr>
<tr>
<td>61</td>
<td>Pristimerin</td>
<td>Quinone methide triterpene</td>
<td>SARS-CoV M₃RO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>130</td>
<td></td>
</tr>
<tr>
<td>S. no.</td>
<td>Name of natural product</td>
<td>Structure</td>
<td>Class of the compound</td>
<td>Potential target(s) (Table 1)</td>
<td>Possible mechanism of action of the compounds</td>
<td>Ref.</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------</td>
<td>-----------</td>
<td>-----------------------</td>
<td>-----------------------------</td>
<td>----------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>62</td>
<td>Tingenone</td>
<td><img src="image" alt="Tingenone structure" /></td>
<td>Quinone methide triterpene</td>
<td>SARS-CoV M^PO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>130</td>
</tr>
<tr>
<td>63</td>
<td>Iguesterin</td>
<td><img src="image" alt="Iguesterin structure" /></td>
<td>Quinone methide triterpene</td>
<td>SARS-CoV M^PO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>130</td>
</tr>
<tr>
<td>64</td>
<td>Tanishone</td>
<td><img src="image" alt="Tanishone structure" /></td>
<td>Abietane diterpene</td>
<td>SARS-CoV M^PO, SARS-CoV PL P^PO</td>
<td>Inhibition of viral life cycle inside host</td>
<td>131</td>
</tr>
<tr>
<td>65</td>
<td>Rutin</td>
<td><img src="image" alt="Rutin structure" /></td>
<td>Flavonoid glycoside</td>
<td>SARS-CoV-2 M^PO, SARS-CoV-2 RdRp</td>
<td>Inhibition of viral life cycle inside host</td>
<td>136</td>
</tr>
<tr>
<td>66</td>
<td>Nicotiflorin</td>
<td><img src="image" alt="Nicotiflorin structure" /></td>
<td>Flavonoid glycoside</td>
<td>SARS-CoV-2 M^PO, SARS-CoV-2 RdRp</td>
<td>Inhibition of viral life cycle inside host</td>
<td>136</td>
</tr>
<tr>
<td>67</td>
<td>Phycocyanobilin</td>
<td><img src="image" alt="Phycocyanobilin structure" /></td>
<td>Marine tetrapyrrole chromophore</td>
<td>SARS-CoV-2 M^PO, SARS-CoV-2 RdRp</td>
<td>Inhibition of viral life cycle inside host</td>
<td>139</td>
</tr>
</tbody>
</table>
showed that terpenoids such as thymoquinone from \textit{Nigella sativa}, salvinorin A from \textit{Salvia divinorum}, bilobalide from \textit{Ginkgo biloba}, menthol from \textit{Mentha}, ginkgolide A from \textit{Ginkgo biloba} and \textit{beta selinene from Apium graveolens} have SARS-CoV M PRO inhibitory action.

Quinone methide triterpenes such as celastrol, pristimerin, tingenone, and iguesterin isolated from \textit{Tripterygium regelii} showed potent inhibitory action against SARS-CoV MPRO.

Tanshinone, which contains the abietane diterpene moiety, isolated from \textit{S. miltiorrhiza} showed selected inhibition against SARS-CoV MPRO and PLPRO. The possible anti-COVID-19 mechanism of action of the compounds mentioned above in this section are compiled in a column in Table 2.

Cardiac glycosides like digitoxin and digoxin were studied during previous pandemics including MERS-CoV and SARS-CoV.\textsuperscript{132,133} The studies found that these cardiac glycosides could inhibit the transmembrane internalization of the virus due to their capacity to deplete the host intracellular potassium which resulted in abrogation of signal transduction of the Na, K-ATPase pump. This in turn resulted in interruption of the viral life cycle in the host. A study by Yang \textit{et al.} in 2005 showed that cardiac glycosides downregulated various cytokines such as NF-\kappa B, TNF\alpha, TNF\beta, etc.\textsuperscript{134} Furthermore, previous studies established that SARS-CoV-2 infection was associated with catastrophic cytokine storm in the target organs.\textsuperscript{135}

So, repurposing of cardiac glycosides for treatment of SARS-CoV-2 can be considered a proper clinical investigation.
found to be potent inhibitors of the SARS-CoV-2 M<sup>PRO</sup> and RdRp via a molecular docking approach.\textsuperscript{136}

Natural products from marine sources: a new-fangled avenue to obtain natural compounds for combating the SARS COVID-19 pandemic

Natural products from marine sources are being used as potential therapeutic agents recently. Marine micro-algae belonging to phyla Rhodophyta and Phaeophyta were studied and the various bioactive compounds like phycocyanin, lutein, polysaccharides, vitamins and other phenolics showed anti-microbial, anticancer, anti-inflammatory, and other crucial pharmacological activities.\textsuperscript{137} Hirata et al. in 2010 studied the anti-viral and antioxidative effects of phycocyanobilins, a class of tetrapyrrole chlorophores present in certain types of marine cyanobacteria.\textsuperscript{138} Pendyala and Patras in 2020 showed that phycocyanobilins demonstrated high binding affinity for the SARS-CoV-2 M<sup>PRO</sup> and RdRp via in silico molecular docking studies.\textsuperscript{139} Lectins are a class of compounds that have affinity for carbohydrates. Griffithsin, a lectin derived from red algae, was studied for its potential application, and studies have shown its anti-viral activity against HIV-1 (ref. 4) and hepatitis-C.\textsuperscript{140,141} A recent in vitro study by Millet et al. showed that griffithsin had inhibitory action against MERS-CoV.\textsuperscript{142} In vitro studies of sulfated polysaccharides or fucoids sourced from brown microalgae Sargassum henslowanum on HSV showed potent inhibitory action.\textsuperscript{143} Kwon et al. in 2020 reported that the fucoids obtained from macroalgae Saccharina japonica had significant anti-viral activity against SARS-CoV-2. Out of the two fucoids involved in their study, the fucoid labelled as RPI-27 showed more potent anti-viral activity than remdesivir. They concluded that fucoids can be co-administered with other anti-viral compounds to elicit potent anti SARS-CoV-2 activity.\textsuperscript{144} Esculetin ethyl ester from marine sponge Axinella cf. corrugate showed strong interaction with SARS-CoV-2 protease to be used as an anti COVID-19 drug.\textsuperscript{145} Carrageenans, a class of marine sulphated polysaccharides, are considered to be inhibitors of several viruses. They act via inhibiting the binding of the virus and their subsequent internalization. Nagle et al. thus speculated the use of these compounds as coating materials on sanitary items to prevent COVID-19 infection.\textsuperscript{145} In recent times, in silico studies contributed towards identifying potential lead compounds for drug development against the COVID-19 pandemic. Khan et al. in their molecular dynamic study came up with 5 potent SARS-CoV-2 M<sup>PRO</sup> inhibitors (fostularin 3, 1-hexadecoxypropane-1,2-diol, palmilute acid, 15alpha-methoxypupehenol and pupehedione) from marine sources which can be utilized for hampering the viral life cycle in the host.\textsuperscript{146} Finding potent natural compounds from marine sources remains a challenge due to the scarce availability, difficult collection, and rarity of marine organisms. In the past few decades, the search for potent natural compounds from marine sources which can exhibit a plethora of activities is going on and is bringing positive results. So we can extrapolate these findings to find a possible cure from the naturally occurring marine organisms.

Possible relationship between the viral protein structure and the functional groups present in the molecular structures of natural metabolites

Naturally derived plant secondary metabolites can be of various classes like polyphenolics, alkaloids, terpenoids, etc. They possess diversity in their structure and the different chemical moieties present in them contributes towards their specific function in biological systems. Polyphenols are a class of natural products having a plethora of activities including anti-viral activity.\textsuperscript{147} Polyphenols like kaempferol (structure in Table 2), herbacetin (structure in Table 2) and rhoifolin (structure in Table 2) share structural similarity. The phenyl moiety of kaempferol and the chroman-4-one moiety are responsible for its binding with the SARS-CoV M<sup>PRO</sup>. Herbacetin has an additional 8-hydroxyl group which results in strong binding to the SARS-CoV M<sup>PRO</sup>. Rhoifolin (structure in Table 2) has a bulky alpha-rhamnopyranosyl beta-D-glucopyranoside moiety along with the chroman-4-one moiety which explains its strong binding to the SARS-CoV M<sup>PRO</sup> since the bulky group fits in the pockets of the protein with hydrogen bonds.\textsuperscript{148} Alkaloids are a diverse group of plant secondary metabolites having different chemical moieties. The different moieties are responsible for their activities. For example, indole alkaloids like 10-hydroxyusambarensine contain the pyrido-indole moiety (structure in Table 2). This pi-bond enriched system is responsible for binding with the amino acid residues present in the SARS-CoV-2 M<sup>PRO</sup> via pi-alkyl interaction. Terpenoids are another important class of natural compounds formed by polymerization of the isoprenoid moiety. Terpenoids having the quinone-methide moiety like iguesterin, pristimerin and tingenone (structures in Table 2) show binding affinity for the SARS-CoV M<sup>PRO</sup> active site. This binding is due to the presence of the OH group in the quinone-methide moiety which forms a hydrogen bond with the CO group of the cysteine and OH group of threonine residues present in the active site of the viral protein. Modification of the hydroxyl group in the quinone-methide moiety resulted in the abrogation of the binding affinity of these terpenoids.\textsuperscript{149} Both the glycone and aglycone moieties of glycosides are responsible for their binding affinity with viral proteins like M<sup>PRO</sup> and RdRp. For example in rutin (structure in Table 2) the OH groups present in the rutinoside moiety forms a hydrogen bond with the amino-acid residues and the aromatic rings undergo pi-pi interaction with the aromatic amino acid residues in the target proteins.\textsuperscript{150} Marine natural products have complex chemical structures and their bulky nature accounts for fitting in the target protein pocket. For example the carbonylamo group and the OH group in the oxa-azispiro moiety of fostularin 3 (structure in Table 2) is responsible for its binding with the serine and methionine residues of the SARS-CoV M<sup>PRO</sup> active site. In another instance the 2 OH groups present in 1-hexadecoxypropane-1,2-diol (structure in Table 2) are
responsible for its binding to the active site pocket of the SARS-CoV M\textsuperscript{PRO}.

In a nutshell it can be concluded that the diverse functional groups present in the different classes of natural compounds are responsible for their binding to the specific target proteins. In silico studies predict the possible ligand-target interaction and pave the way towards finding new drug molecules.

### Conclusion and future prospects

The novel coronavirus (SARS COVID-19) has claimed over a million lives and is still continuing to affect thousands at a daily rate and has proved to be an important target for immediate drug development. More concerning news that shocked the world was the identification of a new variant of the SARS-CoV-2 in the UK, named VUI-202012/01. This new variant had 17 mutations and one of the most significant was the N501Y mutation in the spike protein which could render it more infectious. Laboratories all around the globe are frantically searching for an effective vaccine but it takes time to develop a successful one. According to the WHO there are 3 vaccine candidates which are in the pipeline, but only one (developed by Pfizer) received WHO EUL/PQ authorization. The vaccines developed by Pfizer, Moderna and AstraZeneca are being used on a small to medium scale worldwide and their safety and efficacy results are reported in press conferences and that of AstraZeneca has been published in a peer reviewed journal.\textsuperscript{49}

Till then we must look for small molecules that can effectively reduce the mortality of the virus. Synthetic small molecules like chloroquine and hydroxychloroquine are being used to treat the patients affected by this virus but the limited availability and adverse reactions make this line of treatment somewhat inefficient. It has been known that natural products and plant extracts have potent anti-viral activities and they have shown inhibitory effects on the viral enzymes which are essential for the viral life cycle. From the in silico data received we have compiled a large number of potent anti-viral compounds which need extensive in vitro and in vivo analysis prior to being used as drugs.

### Abbreviations

- **μM**: Micromolar
- **5’ UTR**: 5’ untranslated region
- **ACE2**: Angiotensin-converting enzyme 2
- **ADMET**: Absorption, distribution, metabolism, excretion, and toxicity
- **ARDS**: Acute respiratory distress syndrome
- **CoV**: Coronavirus
- **CPT**: Convalescent plasma therapy
- **DNA**: Deoxyribonucleic acid
- **EC\textsubscript{50}**: Half maximal effective concentration
- **ERGIC**: Endoplasmatic reticulum–Golgi intermediate compartment
- **EUL/PQ**: Emergency use listing procedure
- **GMP**: Good manufacturing practices
- **IC\textsubscript{50}**: Half maximal inhibitory concentration
- **kb**: Kilobase
- **kDa**: Kilodaton
- **M\textsuperscript{PRO}**: Main protease (3C-like protease)
- **mRNA**: Messenger ribonucleic acid
- **NF-κB**: Nuclear factor kappa light chain enhancer of activated B cells
- **nm**: Nanometre
- **NSP**: Non-structural proteins
- **ORF**: Open reading frame
- **PLPRO**: Papain-like protease
- **PP**: Polyproteins
- **PSM**: Plant secondary metabolite
- **RdRp**: RNA dependent RNA polymerase
- **RNA**: Ribonucleic acid
- **RNP**: Ribonucleocapsid
- **SOFA**: Sequential organ failure assessment
- **TGG**: Tetra-O-galloyl-β-D-glucose
- **TMD**: Transmembrane domain
- **TMPRSS2**: Trans membrane protease serine 2
- **TNF\alpha**: Tumor necrosis factor alpha
- **TNF\beta**: Tumor necrosis factor beta
- **US FDA**: United States Food and Drug Administration
- **WHO**: World Health Organization
- **μg/ml**: Micrograms/millilitre

### Conflicts of interest

The authors declare no conflict of interest.

### Acknowledgements

The authors would like to acknowledge the Department of Pharmaceuticals, Ministry of Fertilizer, Government of India for providing the fellowship to Mr Rudra Chakravarti and Mr Rajveer Singh. We would also like to acknowledge the DBT, Govt of India [grant number BT/PR26301/GET/119/258/2017], Govt of West Bengal Department of Biotechnology WBDBT [grant number – BT/P/Budget/RD-74/2017] for their support, and Indian Council of Medical Research for sponsoring Emeritus Professorship to Dr Syamal Roy.

### References


16730 | RSC Adv., 2021, 11, 16731-16735

© 2021 The Author(s). Published by the Royal Society of Chemistry


30 A. J. Te Velthuis, J. J. Arnold, C. E. Cameron, S. H. van den Worm and E. J. Snijder, The RNA polymerase activity of...


48 T. A. Sullivan, Tough Road: Cost to Develop One New Drug is $2.6 Billion; Approval Rate for Drugs Entering Clinical Development is 12%, 2019, available from: https://www.policymed.com/2014/12/a-tough-road-cost-to-develop-one-new-drug-is-26-billion-approval-rate-for-drugs-entering-clinical-de.html.


55 E. S. Amirian and J. K. Levy, Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses, *One Health*, 2020, 100128.


140 S. Lusvarghi and C. A. Bewley, Griffithsin: an antiviral lectin with outstanding therapeutic potential, Viruses, 2016, 8(10), 296.


